Leksell Gamma Knife® Perfexion™ and Elekta Axesse,™ an image-guided radiosurgery treatment solution optimized for neurosurgery, are redefining stereotaxy in radiation medicine. Learn more about how Elekta's new line of stereotactic radiosurgery solutions are creating new possibilities for your most challenging cases by visiting www.elekta.com/proof.
EDITORIAL
133 Teamwork, Cooperation, Innovation: Clues in the Canadian Success of Stroke Care
   Gustavo Saposnik

135 Cerebral Proliferative Angiopathy (CPA)
   Karel terBrugge

136 Managing Unruptured Intracranial Aneurysms
   J. Max Findlay

COMMENTARY
138 Managing Unruptured Aneurysms: The Ethical Solution to the Dilemma
   Jean Raymond

REVIEW ARTICLES
143 Central Nervous System Imaging in Mitochondrial Disorders
   Josef Finsterer

154 Movements in Brain Death: A Systematic Review
   Gustavo Saposnik, Vincenzo S. Basile, G. Bryan Young

ORIGINAL ARTICLES
161 Intravenous Thrombolysis for Acute Ischaemic Stroke in Young Adult Patients
   Alexandre Y. Poppe, Alastair M. Buchan, Michael D. Hill

168 Arterial Onyx Embolisation of Intracranial DAVFs with Cortical Venous Drainage
   Jason Chew, Alain Weill, François Guilbert, Jean Raymond, Marie-Eve Audet, Daniel Roy

176 Comparison of CTA to DSA in Determining the Etiology of Spontaneous ICH
   Robert Yeung, Tabassum Ahmad, Richard I. Aviv, Lyne Noel de Tilly, Allan J. Fox, Sean P. Symons

181 Early Ischemic Stroke Presentation in Pakistan
   Ayeeshia Kamran Kamal, Bhojo Asunmal Khedalani, Sajjad Ahmed Ansari, Maria Afridi, Nadir Ali Syed

187 Selective Amygdalohippocampectomy: Surgical Outcome in Children versus Adults

192 Is Temperature Regulation Different in Children Susceptible to Febrile Seizures
   Kevin E. Gordon, Joseph M. Dooley, Ellen P. Wood, Peggy Bethune

196 Lumbar Discectomy: A National Survey of Neurosurgeons and Literature Review
   Aleksa Cenic, Edward Kachur

201 Percutaneous Muscle Biopsies: Review of 900 Consecutive Cases at London Health Sciences Centre
   Kendra L. Derry, Michael N. Nicholle, Julia A. Keith-Rokosh, Robert R. Hammond

207 Concussion in Hockey: Compliance with Return to Play Advice and Follow-up Status
   Alan Ackery, Christine Providenza, Charles H. Tator

213 High Dose Oral Steroids Commonly Used to Treat Relapses in Canadian MS Clinics
   S.A. Morrow, L.M. Metz, M. Kremenchutzky

216 Migraine: Prevalence and Associated Disability Among Nigerian Undergraduates
   Kolawole Wasiu Wahab, Asuwemhe Johnson Ugheoke

222 Neuroleptic-Induced Tardive Cervical Dystonia: Clinical Series of 20 Patients
   Clecio Godeiro-Junior, Andre C. Felício, Patrícia de Carvalho Aguiar, Vanderci Borges, Sonia M. A. Silva, Henrique B. Ferraz

227 Precentral Knob Corresponds to the Primary Motor and Premotor Area
   N. Shinoura, Y. Suzuki, R. Yamada, Y. Tabei, K. Saito, K. Yagi

234 Resiniferatoxin Mediated Ablation of TRPV1+ Neurons Removes TRPA1 as Well
   László Péce, Péter Pelsócz, Miklós Kecskés, Zoltán Winter, András Papp, Krisztián Kaszás, Tamás Letoha, Csaba Vizler, Zoltán Oláh
NEUROIMAGING HIGHLIGHT

Submitted by: Muneer Eesa, Pranshu Sharma, Mayank Goyal

242

BRIEF COMMUNICATIONS
(formerly Peer Reviewed Letters)

244 Cerebral Schistosomiasis - An Unusual Presentation of an Intracranial Mass Lesion
Jason George, David Rose, Lili-Naz Hazrati, Lance Majl, Mojgan Hodaie

248 In-Stent Stenosis Following Covered Stent-Graft Placement
Justin Flood, Miguel Bussière, Patrick Teefy, Irene Galka, Stephen Lownie, David Pelz

252 Intracranial Hypotension Causing Reversible Frontotemporal Dementia and Coma
Ana-Luiza Sayao, Manraj K.S. Heran, Kristine Chapman, Gary Redekop, Dean Foit

257 Extradural Middle Fossa Approach to a Clear Cell Meningioma in a Child
James King, Michael Cusimano, Cynthia Hawkins, Peter Dirks

262 Cranial Nerve Palsies Associated with Influenza B
Jennifer A. McCombe, Marc J. Narayansingh, Jack H. Jhamandas

265 Books Received/Books Reviewed

A-20 Advertisers Index
A-31 Board of Directors/Committee Chairs
A-12 Calendar of Events
A-11 Classified Ads
A-28 CNSF Congress Preliminary Program
A-9, A-10 Information for Authors
A-27 Thank you to Reviewers

JOURNAL COVER

We are investigating different options for the cover of the Journal and thought it might be appropriate to include pictures of major Canadian Cities and/or Universities as taken by our readers.

If you are interested in submitting pictures, please send them to maggie-mccallion@cnsfederation.org in high resolution format, (i.e. tif or jpeg). Please also indicate your willingness to provide these pictures free of charge. Picture 'acknowledgement' will be provided.
Join us in Halifax, Nova Scotia for the 44th Annual Congress of the Canadian Neurological Sciences Federation.
Cymbalta® (duloxetine hydrochloride) is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN). Cymbalta® is not indicated for use in children under 18 years of age. Rigorous clinical monitoring for suicidal ideation or other indicators of potential for suicidal behaviour is advised in patients of all ages. This includes monitoring for agitation-type emotional and behavioural changes. Please see Prescribing Information for complete warnings.

Patients currently taking Cymbalta® should NOT be discontinued abruptly due to risk of discontinuation symptoms. A gradual reduction in the dose is recommended.

Cymbalta® is contraindicated in patients with end-stage renal disease (requiring dialysis) or with severe renal impairment (estimated creatinine clearance <30 mL/min).

Cymbalta® is contraindicated in patients with any liver disease resulting in hepatic impairment.

Cymbalta® is contraindicated in patients concomitantly taking any of the following medications: monoamine oxidase inhibitors; linezolid or within at least 14 days of discontinuing treatment with an MAOI; potent CYP1A2 inhibitors (e.g. fluvoxamine) and some quinolone antibiotics (e.g. ciprofloxacin or enoxacin); and thioridazine.

Because it is possible that duloxetine and alcohol may interact to cause liver injury or that duloxetine may aggravate pre-existing liver disease, Cymbalta should not ordinarily be prescribed to patients with substantial alcohol use. Physicians should be aware of the signs and symptoms of liver damage and should investigate such symptoms promptly.

In clinical trials, Cymbalta® was associated with an increased risk of mydriasis; therefore, it is contraindicated in patients with uncontrolled narrow-angle glaucoma.

The most commonly observed adverse events in Cymbalta®-treated patients in placebo-controlled DPN trials (incidence of 5% or greater and at least twice the incidence in placebo patients) were: nausea (24%), constipation (9%), dry mouth (8%), vomiting (6%), fatigue (12%), decreased appetite (10%), somnolence (17%), and hyperhidrosis (9%).

Cymbalta® is contraindicated in patients concomitantly taking any of the following medications: monoamine oxidase inhibitors; linezolid or within at least 14 days of discontinuing treatment with an MAOI; potent CYP1A2 inhibitors (e.g. fluvoxamine) and some quinolone antibiotics (e.g. ciprofloxacin or enoxacin); and thioridazine.

Because it is possible that duloxetine and alcohol may interact to cause liver injury or that duloxetine may aggravate pre-existing liver disease, Cymbalta® should not ordinarily be prescribed to patients with substantial alcohol use. Physicians should be aware of the signs and symptoms of liver damage and should investigate such symptoms promptly.

In clinical trials, Cymbalta® was associated with an increased risk of mydriasis; therefore, it is contraindicated in patients with uncontrolled narrow-angle glaucoma.

The most commonly observed adverse events in Cymbalta®-treated patients in placebo-controlled DPN trials (incidence of 5% or greater and at least twice the incidence in placebo patients) were: nausea (24%), constipation (9%), dry mouth (8%), vomiting (6%), fatigue (12%), decreased appetite (10%), somnolence (17%), and hyperhidrosis (9%).

Cymbalta® is contraindicated in patients concomitantly taking any of the following medications: monoamine oxidase inhibitors; linezolid or within at least 14 days of discontinuing treatment with an MAOI; potent CYP1A2 inhibitors (e.g. fluvoxamine) and some quinolone antibiotics (e.g. ciprofloxacin or enoxacin); and thioridazine.

Because it is possible that duloxetine and alcohol may interact to cause liver injury or that duloxetine may aggravate pre-existing liver disease, Cymbalta® should not ordinarily be prescribed to patients with substantial alcohol use. Physicians should be aware of the signs and symptoms of liver damage and should investigate such symptoms promptly.

In clinical trials, Cymbalta® was associated with an increased risk of mydriasis; therefore, it is contraindicated in patients with uncontrolled narrow-angle glaucoma.

The most commonly observed adverse events in Cymbalta®-treated patients in placebo-controlled DPN trials (incidence of 5% or greater and at least twice the incidence in placebo patients) were: nausea (24%), constipation (9%), dry mouth (8%), vomiting (6%), fatigue (12%), decreased appetite (10%), somnolence (17%), and hyperhidrosis (9%).

Cymbalta® is contraindicated in patients concomitantly taking any of the following medications: monoamine oxidase inhibitors; linezolid or within at least 14 days of discontinuing treatment with an MAOI; potent CYP1A2 inhibitors (e.g. fluvoxamine) and some quinolone antibiotics (e.g. ciprofloxacin or enoxacin); and thioridazine.

Because it is possible that duloxetine and alcohol may interact to cause liver injury or that duloxetine may aggravate pre-existing liver disease, Cymbalta® should not ordinarily be prescribed to patients with substantial alcohol use. Physicians should be aware of the signs and symptoms of liver damage and should investigate such symptoms promptly.

In clinical trials, Cymbalta® was associated with an increased risk of mydriasis; therefore, it is contraindicated in patients with uncontrolled narrow-angle glaucoma.

The most commonly observed adverse events in Cymbalta®-treated patients in placebo-controlled DPN trials (incidence of 5% or greater and at least twice the incidence in placebo patients) were: nausea (24%), constipation (9%), dry mouth (8%), vomiting (6%), fatigue (12%), decreased appetite (10%), somnolence (17%), and hyperhidrosis (9%).

Cymbalta® is contraindicated in patients concomitantly taking any of the following medications: monoamine oxidase inhibitors; linezolid or within at least 14 days of discontinuing treatment with an MAOI; potent CYP1A2 inhibitors (e.g. fluvoxamine) and some quinolone antibiotics (e.g. ciprofloxacin or enoxacin); and thioridazine.

Because it is possible that duloxetine and alcohol may interact to cause liver injury or that duloxetine may aggravate pre-existing liver disease, Cymbalta® should not ordinarily be prescribed to patients with substantial alcohol use. Physicians should be aware of the signs and symptoms of liver damage and should investigate such symptoms promptly.

In clinical trials, Cymbalta® was associated with an increased risk of mydriasis; therefore, it is contraindicated in patients with uncontrolled narrow-angle glaucoma.

The most commonly observed adverse events in Cymbalta®-treated patients in placebo-controlled DPN trials (incidence of 5% or greater and at least twice the incidence in placebo patients) were: nausea (24%), constipation (9%), dry mouth (8%), vomiting (6%), fatigue (12%), decreased appetite (10%), somnolence (17%), and hyperhidrosis (9%).

Cymbalta® is contraindicated in patients concomitantly taking any of the following medications: monoamine oxidase inhibitors; linezolid or within at least 14 days of discontinuing treatment with an MAOI; potent CYP1A2 inhibitors (e.g. fluvoxamine) and some quinolone antibiotics (e.g. ciprofloxacin or enoxacin); and thioridazine.

Because it is possible that duloxetine and alcohol may interact to cause liver injury or that duloxetine may aggravate pre-existing liver disease, Cymbalta® should not ordinarily be prescribed to patients with substantial alcohol use. Physicians should be aware of the signs and symptoms of liver damage and should investigate such symptoms promptly.
AZILECT® (rasagiline mesylate) is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease as initial monotherapy and as adjunct therapy to levodopa.

AZILECT® is contraindicated with meperidine, tramadol, methadone, propoxyphene, dextromethorphan, St. John's wort, cyclobenzaprine, sympathomimetic amines, antidepressants and other MAO inhibitors. Patients taking AZILECT® should not undergo elective surgery requiring general anesthesia. AZILECT® is contraindicated in patients with pheochromocytoma. AZILECT® may cause hallucinations and as an adjunct to levodopa there is the possibility of increased dyskinesia and postural hypotension. AZILECT® should not be used at daily doses exceeding the maximum recommended (1 mg/day) because of the risks associated with nonselective inhibition of MAO. Patients taking ciprofloxacin and other CYP1A2 inhibitors should use 0.5 mg daily of AZILECT®.

No significant differences in safety profile were observed based on age or gender. Overall, in phase III clinical trials, the long-term safety profile was similar to that observed with shorter duration exposure.

The most commonly observed adverse events that occurred in ≥5% of patients and were at least 1.5 times the incidence in the placebo group were flu syndrome (5%, 1%), arthralgia (7%, 4%), depression (5%, 2%), dyspepsia (7%, 4%) and falls (5%, 3%) in patients receiving AZILECT® 1 mg as monotherapy; and dyskinesia (18%, 10%), accidental injury (12%, 5%), weight loss (9%, 3%), postural hypotension (9%, 3%), vomiting (7%, 1%), anorexia (5%, 1%), arthralgia (6%, 4%), abdominal pain (6%, 1%), nausea (12%, 8%), constipation (6%, 5%), dry mouth (6%, 3%), rash (6%, 3%), ecchymosis (6%, 3%), somnolence (6%, 4%) and paresthesia (5%, 3%) for AZILECT® 1 mg as adjunct therapy.

1 Comparative clinical significance unknown.

AZILECT® (rasagiline mesylate) is a registered trademark of Teva Pharmaceutical Industries Ltd and is used under licence. TEVA and the design thereof are registered trademarks of Teva Pharmaceutical Industries Ltd and are used under licence. ©2009 Teva Neuroscience G.P. - S.E.N.C. Montreal, Quebec H3A 3L4

See prescribing summary on page A-23-26
MAXALT® (rizatriptan benzoate) is indicated for the acute treatment of migraine attacks with or without aura in adults. MAXALT® is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic, ophthalmoplegic or basilar migraine. Safety and effectiveness of MAXALT® have not been established for cluster headache, which is present in an older, predominantly male population.

MAXALT® is contraindicated in patients with history, symptoms, or signs of ischemic cardiac, cerebrovascular or peripheral vascular syndromes, valvular heart disease or cardiac arrhythmias (especially tachycardias). In addition, patients with other significant underlying cardiovascular diseases should not receive MAXALT®.

MAXALT® is also contraindicated in patients with uncontrolled or severe hypertension.

MAXALT® is contraindicated in co-administration with monoamine oxidase (MAO) inhibitors within 2 weeks after discontinuation of treatment, and within 24 hours of administration of 5-HT₃ agonists or ergot-type medications. For a complete list of contraindications, please consult the Product Monograph.

The recommended single adult dose is 5 mg. The maximum recommended single dose is 10 mg.

The most common adverse events during treatment with MAXALT® (rizatriptan benzoate) tablets 10 mg were dizziness (8.9%), somnolence (8.4%), asthenia/fatigue (6.9%), nausea (5.7%) and pain/pressure sensation (chest, 3.1%; neck/throat/jaw, 2.5%; upper limb, 1.8%).

The most common adverse events during treatment with MAXALT RPD® (rizatriptan benzoate) wafers 10 mg were dizziness (8.6%), nausea (7.0%), dry mouth (6.0%), somnolence (5.3%), asthenia/fatigue (3.6%), and pain/pressure sensation (chest, 1.7%; neck/throat/jaw, 2.0%; upper limb, 2.0%).

MAXALT RPD® wafers contain phenylalanine (a component of aspartame).

*The wafer will dissolve rapidly and be swallowed with saliva. No liquid is needed to take the wafer. **RPD = Rapidly dissolving

References:

BEFORE PRESCRIBING MAXALT® PLEASE CONSULT THE ENCLOSED PRESCRIBING INFORMATION.
PRODUCT MONOGRAPH AVAILABLE FOR DOWNLOAD AT www.merckfrosst.com

*Registered Trademarks of Merck & Co., Inc. Used under license.

Please visit our website at: www.merckfrosst.com
LYRICA (pregabalin) is an analgesic indicated for the management of neuropathic pain (NeP) associated with DPN and PHN.

LYRICA is contraindicated in patients who are hypersensitive to pregabalin or to any ingredient in the formulation or component of the container.

The most commonly observed adverse events are headache and nausea.

LYRICA may be useful in the management of central neuropathic pain (NeP) in adult patients for which it has been issued marketing authorization with conditions to reflect the promising nature of the clinical evidence and the need for a confirmatory study to verify its clinical benefit. Patients should be advised before treatment.


- Pain relief shown in postherpetic neuralgia (PHN) and central NeP as early as week 1 and demonstrated over 3 months4,5.
- Improvement shown in pain-related sleep interference in PHN and central NeP as early as week 1 and demonstrated over 3 months1,4,7.

Significant improvement in overall status.

- Significant improvement demonstrated in patient-reported overall status (Patient Global Impression of Change [PGIC]) in patients with peripheral NeP [diabetic peripheral neuropathy (DPN) or PHN] and central NeP1,3-5,7.

Dosage reduction is required in patients with renal impairment (creatinine clearance <60 mL/min) as LYRICA is primarily eliminated by renal excretion.

Please see Prescribing Information for complete Warnings and Precautions, Adverse Reactions, Dosage and Administration and patient selection criteria.

References:
1. Data on file. Pfizer Canada Inc. Study 1008-196

* A 13-week, multidose, double-blind, placebo-controlled trial in 363 patients with PHN. A significant difference in pain reduction was shown over placebo for all doses: 150 mg/day, 300 mg/day, and 600 mg/day (p<0.01 for all doses). PGIC was reported as (at least minimally) improved by 56.5% and 21.5% of patients in the LYRICA and placebo treatment groups, respectively. Discontinuation rates due to adverse events for LYRICA and placebo, respectively, were 9% and 4% in DPN, 14% and 7% in PHN and 21% and 13% in central NeP.

For complete Warnings and Precautions, Adverse Reactions, Dosage and Administration and patient selection criteria, please refer to the Prescribing Information.